April 2024
1. TAMARGO IA, Baek KI, Xu C, Kang DW, et al
   HEG1 Protects Against Atherosclerosis by Regulating Stable Flow-Induced KLF2/4 Expression in Endothelial Cells.
   Circulation. 2024;149:1183-1201.
   

   >> Share

   
   February 2024
2. STONE NJ, Blum C
   If Action is Delayed, Is Survival Denied? Management of Severe Hypercholesterolemia Is Important and Urgent.
   Circulation. 2024;149:427-429.
   

   >> Share

   
   January 2024
3. SANTOS RD, Cuchel M
   LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.
   Circulation. 2024;149:363-366.
   

   >> Share

   
   November 2023
4. YALCINKAYA M, Liu W, Thomas LA, Olszewska M, et al
   BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis.
   Circulation. 2023;148:1764-1777.
   

   >> Share

   
   
5. MILES J, Scotti A, Castagna F, Kuno T, et al
   Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort.
   Circulation. 2023 Nov 16. doi: 10.1161/CIRCULATIONAHA.123.064566.
   

   >> Share

   
   October 2023
6. WIEGMAN A, Greber-Platzer S, Ali S, Doortje Reijman M, et al
   Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
   Circulation. 2023 Oct 20. doi: 10.1161/CIRCULATIONAHA.123.065529.
   

   >> Share

   
   
7. RAAL F, Durst R, Bi R, Talloczy Z, et al
   Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
   Circulation. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.122.063460.
   

   >> Share

   
   September 2023
8. ALDANA-BITAR J, Karlsberg RP, Budoff MJ
   Letter by Aldana-Bitar et al Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
   Circulation. 2023;148:1057.
   

   >> Share

   
   
9. PEREZ DE ISLA L, Saltijeral Cerezo A, Mata P
   Response by Perez de Isla et al to Letter Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
   Circulation. 2023;148:1059-1060.
   

   >> Share

   
   
10. LONG X, Jiang M
    Letter by Long and Jiang Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1058.
    

    >> Share

    
    July 2023
11. LAGU T, Schroth SL, Haywood C, Heinemann A, et al
    Diagnosis and Management of Cardiovascular Risk in Individuals With Spinal Cord Injury: A Narrative Review.
    Circulation. 2023;148:268-277.
    

    >> Share

    
    
12. JOHNS DG, Campeau LC, Banka P, Bautmans A, et al
    Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
    Circulation. 2023;148:144-158.
    

    >> Share

    
    May 2023
13. ZHANG Y, Dron JS, Bellows BK, Khera AV, et al
    Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease.
    Circulation. 2023;147:1556-1559.
    

    >> Share

    
    April 2023
14. PEREZ DE ISLA L, Diaz-Diaz JL, Romero MJ, Muniz-Grijalvo O, et al
    Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
    Circulation. 2023 Apr 3. doi: 10.1161/CIRCULATIONAHA.122.062557.
    

    >> Share

    
    October 2022
15. SHOTWELL MK, Vorla M, Kalra DK
    Very High Cholesterol Mimicking Homozygous Familial Hypercholesterolemia.
    Circulation. 2022;146:1182-1188.
    

    >> Share

    
    August 2022
16. RIDKER PM, Rifai N, MacFadyen J, Glynn RJ, et al
    Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1beta, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholi
    Circulation. 2022;146:372-379.
    

    >> Share

    
    May 2022
17. BERGMARK BA, Marston NA, Bramson CR, Curto M, et al
    Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
    Circulation. 2022;145:1377-1386.
    

    >> Share

    
    February 2022
18. SEMOVA I, Levenson AE, Krawczyk J, Bullock K, et al
    Insulin Prevents Hypercholesterolemia by Suppressing 12a-Hydroxylated Bile Acid Production.
    Circulation. 2022 Feb 23. doi: 10.1161/CIRCULATIONAHA.120.045373.
    

    >> Share

    
    June 2021
19. KUEHN BM
    Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price Tag.
    Circulation. 2021;143:2494-2496.
    

    >> Share

    
    
20. ROHATGI A, Westerterp M, von Eckardstein A, Remaley A, et al
    HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research.
    Circulation. 2021;143:2293-2309.
    

    >> Share

    
    April 2021
21. POWELL-WILEY TM, Poirier P, Burke LE, Despres JP, et al
    Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association.
    Circulation. 2021 Apr 22:CIR0000000000000973. doi: 10.1161/CIR.0000000000000973.
    

    >> Share

    
    November 2020
22. KULLO IJ
    Familial Hypercholesterolemia: A Reportable Disorder.
    Circulation. 2020;142:1999-2001.
    

    >> Share

    
    October 2020
23. MSZAR R, Nasir K, Santos RD
    Coronary Artery Calcification in Familial Hypercholesterolemia: An Opportunity for Risk Assessment and Shared Decision Making With the Power of Zero?
    Circulation. 2020;142:1405-1407.
    

    >> Share

    
    June 2020
24. KHERA AV, Hegele RA
    What Is Familial Hypercholesterolemia, and Why Does It Matter?
    Circulation. 2020;141:1760-1763.
    

    >> Share

    
    
25. HOVINGH GK, Lepor NE, Kallend D, Stoekenbroek RM, et al
    Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
    Circulation. 2020;141:1829-1831.
    

    >> Share

    
    May 2020
26. HU P, Dharmayat KI, Stevens CAT, Sharabiani MTA, et al
    Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.
    Circulation. 2020 May 29. doi: 10.1161/CIRCULATIONAHA.119.044795.
    

    >> Share

    
    
27. LOUPY A, Coutance G, Bonnet G, Van Keer J, et al
    Identification and characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population Based Study.
    Circulation. 2020 May 4. doi: 10.1161/CIRCULATIONAHA.119.044924.
    

    >> Share

    
    April 2020
28. STONE NJ, Blumenthal RS, Lloyd-Jones D, Grundy SM, et al
    Comparing Primary Prevention Recommendations: A Focused Look at United States and European Guidelines on Dyslipidemia.
    Circulation. 2020;141:1117-1120.
    

    >> Share

    
    
29. VIRANI SS, Smith SC Jr, Stone NJ, Grundy SM, et al
    Secondary Prevention for Atherosclerotic Cardiovascular Disease: Comparing Recent US and European Guidelines on Dyslipidemia.
    Circulation. 2020;141:1121-1123.
    

    >> Share

    
    November 2019
30. DAMASK A, Steg PG, Schwartz GG, Szarek M, et al
    Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial.
    Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044434.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share